2 patents
Utility
Antibody-coupled T Cell Receptor Constructs and Therapeutic Uses Thereof
10 Jun 20
Disclosed herein are antibody-coupled T cell receptor (ACTR) polypeptides comprising: a CD16A extracellular domain, a transmembrane domain, one or more co-stimulatory signaling domains, at least one of which is a CD28 co-stimulatory signaling domain, and a CD3z cytoplasmic signaling domain.
Kathleen MCGINNESS, Gregory MOTZ, Michael FRAY, Birgit SCHULTES, James HEMPHILL, James KIM, Tooba CHEEMA, Taylor HICKMAN
Filed: 29 Jan 18
Utility
Co-use of Anti-bcma Antibody and Antibody-coupled T Cell Receptor (Actr) In Cancer Therapy and B Cell Disorders
18 Dec 19
Disclosed herein are methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BCMA antibody and an effective amount of T lymphocytes and/or NK cells expressing an antibody-coupled T-cell receptor (ACTR) construct, which may comprises an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig); a transmembrane domain; optionally one or more of co-stimulatory domains, and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM).
Heather HUET, Seth ETTENBERG, Django SUSSMAN, Tooba CHEEMA, Taylor HICKMAN, Katie O'CALLAGHAN, Maureen RYAN
Filed: 15 Feb 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first